Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib vs Best Supportive Care in Egyptian HCC Patients
NCT02971696Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Dec 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Best Supportive Care (2 arms). Primary endpoints: Overall Survival at 12 months and Event Free Survival at 12 months. Started Dec 2016; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02971696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971696.